Fractalkine has anti-apoptotic and proliferative effects on human vascular smooth muscle cells via epidermal growth factor receptor signalling

Cardiovascular Research

Volumn 85, Issue 4, 2010, Pages 825-835

  White, Gemma E ^a   Tan, Thomas C C ^a   John, Alison E ^a,c   Whatling, Carl ^b   McPheat, William L ^b   Greaves, David R ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b ASTRAZENECA R AND D   (Sweden)

^c UNIVERSITY OF NOTTINGHAM   (United Kingdom)

Author keywords

Anti apoptosis; Chemokine; CX3CL1; CX3CR1; EGFR; Epiregulin; Fractalkine; Proliferation; Smooth muscle cell

Indexed keywords

APOPTOSIS INHIBITOR; AZ 12201182; CASPASE 3; CASPASE 7; CHEMOKINE RECEPTOR ANTAGONIST; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIREGULIN; FRACTALKINE; LIPOCORTIN 5; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE; MITOGENIC AGENT; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; STAUROSPORINE; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CELL PROLIFERATION; CELL SURVIVAL; CONTROLLED STUDY; CORONARY ARTERY; DNA SYNTHESIS; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; MITOGENESIS; MITOSIS INHIBITION; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; SIGNAL TRANSDUCTION; SMOOTH MUSCLE FIBER; VASCULAR SMOOTH MUSCLE; WESTERN BLOTTING;

1-PHOSPHATIDYLINOSITOL 3-KINASE; APOPTOSIS; ATHEROSCLEROSIS; CELL DIVISION; CELLS, CULTURED; CHEMOKINE CX3CL1; CORONARY VESSELS; EPIDERMAL GROWTH FACTOR; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; GENE EXPRESSION; HUMANS; MITOGENS; MUSCLE, SMOOTH, VASCULAR; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS C-AKT; RECEPTOR, EPIDERMAL GROWTH FACTOR; SIGNAL TRANSDUCTION;

EID: 76749116162     PISSN: 00086363     EISSN: 17553245     Source Type: Journal    
DOI: 10.1093/cvr/cvp341     Document Type: Article

References (27)

1. Charo IF, Ransohoff RM. The many roles of chemokines and chemokine receptors in inflammation. N Engl J Med 2006;354:610-621.
2. Fong AM, Robinson LA, Steeber DA, Tedder TF, Yoshie O, Imai T et al. Fractalk-ine and CX3CR1 mediate a novel mechanism of leukocyte capture, firm adhesion, and activation under physiologic flow. J Exp Med 1998;188:1413-1419.
3. Bazan JF, Bacon KB, Hardiman G, Wang W, Soo K, Rossi D et al. A new class of membrane-bound chemokine with a CX3C motif. Nature 1997;385:640-644.
4. Ludwig A, Berkhout T, Moores K, Groot P, Chapman G. Fractalkine is expressed by smooth muscle cells in response to IFN-gamma and TNF-alpha and is modulated by metalloproteinase activity. J Immunol 2002;168:604-612.
5. Greaves DR, Hakkinen T, Lucas AD, Liddiard K, Jones E, Quinn CM et al. Linked chromosome 16q13 chemokines, macrophage-derived chemokine, fractalkine, and thymus-and activation-regulated chemokine, are expressed in human atherosclerotic lesions. Arterioscler Thromb Vasc Biol 2001;21:923-929.
6. Garton KJ, Gough PJ, Blobel CP, Murphy G, Greaves DR, Dempsey PJ et al. Tumor necrosis factor-alpha-converting enzyme (ADAM17) mediates the cleavage and shedding of fractalkine (CX3CL1). J Biol Chem 2001;276:37993-38001.
7. Imai T, Hieshima K, Haskell C, Baba M, Nagira M, Nishimura M et al. Identification and molecular characterization of fractalkine receptor CX3CR1, which mediates both leukocyte migration and adhesion. Cell 1997;91:521-530.
8. Lucas AD, Bursill C, Guzik TJ, Sadowski J, Channon KM, Greaves DR. Smooth muscle cells in human atherosclerotic plaques express the fractalkine receptor CX3CR1 and undergo chemotaxis to the CX3C chemokine fractalkine (CX3CL1). Circulation 2003;108:2498-2504.
9. Ruth JH, Volin MV, Haines GK 3rd, Woodruff DC, Katschke KJ Jr, Woods JM et al. Fractalkine, a novel chemokine in rheumatoid arthritis and in rat adjuvant-induced arthritis. Arthritis Rheum 2001;44:1568-1581.
10. Robinson LA, Nataraj C, Thomas DW, Howell DN, Griffiths R, Bautch V et al. A role for fractalkine and its receptor (CX3CR1) in cardiac allograft rejection. J Immunol 2000;165:6067-6072.
11. Moatti D, Faure S, Fumeron F, Amara Mel W, Seknadji P, McDermott DH et al. Polymorphism in the fractalkine receptor CX3CR1 as a genetic risk factor for coronary artery disease. Blood 2001;97:1925-1928.
12. Lavergne E, Labreuche J, Daoudi M, Debre P, Cambien F, Deterre P et al. Adverse associations between CX3CR1 polymorphisms and risk of cardiovascular or cer-ebrovascular disease. Arterioscler Thromb Vasc Biol 2005;25:847-853.
13. Combadiere C, Potteaux S, Gao JL, Esposito B, Casanova S, Lee EJ et al. Decreased atherosclerotic lesion formation in CX3CR1/apolipoprotein E double knockout mice. Circulation 2003;107:1009-1016. (Pubitemid 36258725)
14. Teupser D, Pavlides S, Tan M, Gutierrez-Ramos JC, Kolbeck R, Breslow JL. Major reduction of atherosclerosis in fractalkine (CX3CL1)-deficient mice is at the bra-chiocephalic artery, not the aortic root. Proc Natl Acad Sci USA 2004;101: 17795-17800.
15. Boyle JJ, Bowyer DE, Weissberg PL, Bennett MR. Human blood-derived macro-phages induce apoptosis in human plaque-derived vascular smooth muscle cells by Fas-Ligand/Fas interactions. Arterioscler Thromb Vasc Biol 2001;21:1402-1407.
16. Prenzel N, Zwick E, Daub H, Leserer M, Abraham R, Wallasch C et al. EGF receptor transactivation by G-protein-coupled receptors requires metalloproteinase cleavage of proHB-EGF. Nature 1999;402:884-888.
17. Zhang H, Chalothorn D, Jackson LF, Lee DC, Faber JE. Transactivation of epidermal growth factor receptor mediates catecholamine-induced growth of vascular smooth muscle. Circ Res 2004;95:989-997.
18. Kodali R, Hajjou M, Berman AB, Bansal MB, Zhang S, Pan JJ et al. Chemokines induce matrix metalloproteinase-2 through activation of epidermal growth factor receptor in arterial smooth muscle cells. Cardiovasc Res 2006;69: 706-715.
19. Sahin U, Weskamp G, Kelly K, Zhou H-M, Higashiyama S, Peschon J et al. Distinct roles for ADAM10 and ADAM17 in ectodomain shedding of six EGFR ligands. J Cell Biol 2004;164:769-779.
20. Landsman L, Bar-On L, Zernecke A, Kim K-W, Krauthgamer R, Shagdarsuren E et al. CX3CR1 is required for monocyte homeostasis and atherogenesis by promoting cell survival. Blood 2009;113:963-972.
21. Vantler M, Caglayan E, Zimmermann WH, Baumer AT, Rosenkranz S. Systematic evaluation of anti-apoptotic growth factor signaling in vascular smooth muscle cells. Only phosphatidylinositol 3'-kinase is important. J Biol Chem 2005;280: 14168-14176.
22. Leu CM, Chang C, Hu C. Epidermal growth factor (EGF) suppresses staurosporine-induced apoptosis by inducing mcl-1 via the mitogen-activated protein kinase pathway. Oncogene 2000;19:1665-1675.
23. Yue TL, Wang X, Sung CP, Olson B, McKenna PJ, Gu JL et al. Interleukin-8. A mitogen and chemoattractant for vascular smooth muscle cells. Circ Res 1994; 75:1-7.
24. Viedt C, Vogel J, Athanasiou T, Shen W, Orth SR, Kubler W et al. Monocyte che-moattractant protein-1 induces proliferation and interleukin-6 production in human smooth muscle cells by differential activation of nuclear factor-kappaB and activator protein-1. Arterioscler Thromb Vasc Biol 2002;22:914-920.
25. Cambien B, Pomeranz M, Schmid-Antomarchi H, Millet MA, Breittmayer V, Rossi B et al. Signal transduction pathways involved in soluble fractalkine-induced monocytic cell adhesion. Blood 2001;97:2031-2037.
26. Taylor DS, Cheng X, Pawlowski JE, Wallace AR, Ferrer P, Molloy CJ. Epiregulin is a potent vascular smooth muscle cell-derived mitogen induced by angiotensin II, endothelin-1, and thrombin. Proc Natl Acad Sci USA 1999;96:1633-1638.
27. Takahashi M, Hayashi KI, Yoshida K, Ohkawa Y, Komurasaki T, Kitabatake A et al. Epiregulin as a major autocrine/paracrine factor released from ERK-and p38MAPK-activated vascular smooth muscle cells. Circulation 2003;108: 2524-2529.